Supplementary file 1_Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States.docx

Because migraine disproportionately affects women, this study evaluated sex-related differences in the context of rimegepant for STP.</p>Methods<p>A cross-sectional observational study collected real-world data via an online survey. Eligible subjects were US residents aged ≥18 years with self-reported episodic or chronic migraine, receiving rimegepant, initiated ≥3 months, and taken within 30 days of survey completion.

Reported p values are nominal (unadjusted).</p>Results<p>Of 425 adults, 152 used rimegepant for STP (female, n = 98 [64.5%]; male, n = 54 [35.5%]). Women were more likely than men to use rimegepant for STP due to doctor recommendation (69.4% vs. 48.1%, p = 0.014), frequency (43.9% vs. 25.9%, p = 0.036), and severity of attacks (43.9% vs. 22.2%, p = 0.008). In women and men, stress (women, 74.5%; men, 59.3%), disruptive sleeping patterns (women, 53.1%; men, 35.2%), and noise (women, 48.0%; men, 35.2%) were the most common factors provocative of a migraine attack.